- Diagnostic Différentiel
Drug Information for ELMIRON -100 mg (pentosan polysulfate sodium) Capsules (Ortho-McNeil-Janssen Pharmaceuticals, Inc.): OVERDOSAGE
- CLINICAL TRIALS
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Patient Leaflet
- PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label
- Liens externes liés à ELMIRON -100 mg (pentosan polysulfate sodium) Capsules (Ortho-McNeil-Janssen Pharmaceuticals, Inc.)
Overdose has not been reported. Based upon the pharmacodynamics of the drug, toxicity is likely to be reflected as anticoagulation, bleeding, thrombocytopenia, liver function abnormalities, and gastric distress. (See CLINICAL PHARMACOLOGY and PRECAUTIONS sections.) At a daily dose of 900 mg for 32 weeks (n = 127) in a clinical trial, rectal hemorrhage was reported as an adverse event in 15% of patients. At a daily dose of ELMIRON® 900 mg for 16 weeks in a clinical trial that enrolled 51 patients in the ELMIRON® group and 49 in the placebo group, elevated liver function tests were reported as an adverse event in 11.8% of patients in the ELMIRON® group and 2% of patients in the placebo group. In the event of acute overdosage, the patient should be given gastric lavage if possible, carefully observed and given symptomatic and supportive treatment.
- Drug Information Provided by National Library of Medicine (NLM).